Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.

In the Vorinostat arm, a favorable trend toward improvement in median PFS (6 months versus 4,1 months in the placebo arm) and OS (13 months in the Vorinostat arm versus 9,7 months in the placebo arm) was clearly shown although at the price of an increased toxicity.

also in 1,335 other papers